BrainStorm to Host Call Following President Trump’s Citing of Company’s ALS Treatment During “Right-to-Try” Bill Signing

rainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that the company will host a “Right-to-Try” (RTT) discussion call on Thursday, June 7th at 8:15am EDT.

On May 30, 2018, President Trump signed “Right-to-Try” legislation, which will enable terminally ill patients expanded access to experimental therapies that do not yet have approval by the U.S. Food and Drug Administration (FDA). During the signing, President Trump highlighted the urgency and need for patients who don’t meet inclusion criteria’s to have access to investigational treatments when they have exhausted all treatment options. He cited the example of Matthew Bellina, an amyotrophic lateral sclerosis (ALS) patient who had been seeking access to BrainStorm’s NurOwn® investigational therapy but did not qualify for clinical trials in the U.S.  Mr. Bellina had plans to travel to Israel to pursue access to NurOwn® treatment. The President stated clearly that, with the passage of this bill, patients will be able to seek treatment in the U.S. without the burden of having to travel overseas. BrainStorm’s president and CEO Chaim Lebovits was present during the bill signing at the White House to support and demonstrate commitment to the ALS community.

To view President Trump’s speech on C-SPAN (referencing ALS treatment in Israel at timecode 19:35 through 20:35) refer to

“Since the signing of the ‘Right-to-Try’ bill, we have had numerous enquiries from patients, patient advocates and physicians who want to voice their opinions as we establish our RTT policy,” stated Mr. Lebovits. “As part of our commitment to the community, we are happy to provide interested groups this opportunity to engage directly with us. We recognize the sense of urgency of ALS patients such as Matthew Bellina, and are evaluating ways to provide access to NurOwn® outside of our Phase 3 trial. At the same time, we remain fully focused on completing our Phase 3 trial of NurOwn® as rapidly as possible.”

Members of BrainStorm’s senior management team, including Chaim Lebovits, president and CEO and Ralph Kern, M.D., MHSc, CMO and COO, will host a conference call and webcast for the ALS community and interested participants on Thursday, June 7 at 8:15am Eastern Time.

Israël Science Info